

**Disclosure Team**

The Association of the British Pharmaceutical Industry  
7th Floor, Southside  
105 Victoria Street  
London  
SW1E 6QT

**Date: 28/07/2020**

**Disclosure of transfers of value to healthcare professionals and healthcare organisations**

Dear Disclosure Team,

Syner-Med (PP) Ltd. is currently not member of ABPI, however, voluntarily agreed to abide by ABPI Code of Practice in all aspects of commercial and non-commercial activities, particularly interactions with healthcare professionals (HCPs) and healthcare organisations (HCOs). Syner-Med follows the ABPI Code of Practice with regards to any payments (Sponsorships, Registration fee, honoraria etc.) made to HCPs and HCOs in accordance to Clause 1.4, 1.9, 20, 21, 22, 23 & 24.

**METHODOLOGY**

Syner-Med has Policies and Standard Operating Procedures (SOP) in place in line with ABPI Code of Practice, e.g. Sponsorship/Grant Requests, Advisory Boarding, Meetings and Hospitality and all such requests are processed and approved as per relevant policies and SOPs. Honoraria for consultancy work or Advisory Board meetings etc. are calculated on Fair Market Value (FMV) based on HCPs' role, seniority, time (excluding travel times), hourly/daily rates and industry average.

Syner-Med maintains complete record of all sponsorship/grant requests and payment made to HCPs and HCOs. In the disclosure template multiple payments made have been aggregated into one entry for each HCP or HCO. Amount paid are then subdivided into appropriate categories, i.e. sponsorship, registration, honorarium, travel and accommodation expenses.

In column AC – rows 5-6 of the disclosure template, amounts paid to each HCP during 2019 have been summed. Total of the payments made to all HCPs in 2019 by Syner-Med (PP) Ltd is £20,393.62. Syner-Med made a total payments of £9,484.00 to HCOs in 2019 as grants and sponsorships.



However, Syner-Med has made payments of a total of £9,010.00 to HCOs for non-interventional multicentre prospective audit and for a randomised clinical trial (£15,220.25). All of which have been documented in Research and Development as per Clause 23.2 in column Z – row 50. The total amount of which is £24,230.25. In line with the requirements of ABPI and due to the Covid-19 Pandemic an aggregate declaration of these values have also been submitted for 2019.

Should you require any further information in this matter, please do not hesitate to contact me.

Victoria Thompson

Finance and Compliance Supervisor

Direct Line: 02086556385

Email: [victoriat@syner-med.com](mailto:victoriat@syner-med.com)

